TRENTON, N.J. -- An experimental vaccine to prevent the most common forms of cervical cancer proved 100 percent effective in a two-year test on more than 10,000 girls and women, drug maker Merck & Co. says.\nMerck is hoping to win Food and Drug Administration approval for the vaccine, Gardasil, and put it on the market as soon as late 2006. It would be the first vaccine to prevent cervical cancer, a disease caused almost exclusively by a highly common sexually transmitted virus called the human papilloma virus, or HPV.\nDoctors expect the vaccine to be routinely offered to girls -- and boys, too, because they can spread the virus to their partners -- before they become sexually active, though the practice is certain to run into opposition from conservatives and religious groups.\nWorldwide, cervical cancer is one of the most common cancers among women. It kills nearly 300,000 a year, including about 3,700 in the United States. About 20 million Americans have some form of HPV, which in addition to cervical cancer can cause painful genital warts.\nThe genetically engineered vaccine prevents cervical cancer by blocking infection from the two strains of HPV that cause 70 percent of all cases of the disease.\nThe study, which was funded by Merck, was presented Friday at a meeting of the Infectious Diseases Society of America.\n
Particles
Cervical cancer vaccine effective
Get stories like this in your inbox
Subscribe


